Regeneron Pharmaceuticals Inc (REGN, Financial) has recently captured the attention of investors and financial analysts alike, thanks to its solid financial performance and promising growth prospects. With a current share price of $938.02 and a modest daily gain of 0.04%, despite a slight three-month dip of -0.78%, the company stands out in the biotechnology sector. A detailed analysis, supported by the GF Score, positions Regeneron Pharmaceuticals Inc for significant future growth.
What Is the GF Score?
The GF Score is a proprietary ranking system developed by GuruFocus, assessing stocks across five key valuation aspects. These aspects have been proven to correlate strongly with long-term stock performance from 2006 to 2021. Stocks with higher GF Scores typically yield higher returns. The GF Score ranges from 0 to 100, with 100 indicating the highest potential for outperformance. Regeneron Pharmaceuticals Inc boasts a GF Score of 94, signaling strong future performance potential.
- Financial strength rank: 9/10
- Profitability rank: 10/10
- Growth rank: 10/10
- GF Value rank: 3/10
- Momentum rank: 9/10
Understanding Regeneron Pharmaceuticals Inc's Business
Regeneron Pharmaceuticals, with a market cap of $103.36 billion and annual sales of $13.12 billion, operates with a robust operating margin of 32.27%. The company is a leader in biotechnology, focusing on developing treatments for eye disease, cardiovascular disease, cancer, and inflammation. Its key products include Eylea, Praluent, Dupixent, Libtayo, and Kevzara. Regeneron is also at the forefront of innovation through partnerships in RNAi and CRISPR-based gene editing technologies.
Financial Strength Breakdown
Regeneron Pharmaceuticals Inc's financial robustness is evident through its impressive Interest Coverage ratio of 57.99 and an Altman Z-Score of 11.28, indicating a strong shield against financial distress. The company's strategic debt management is reflected in its Debt-to-Revenue ratio of 0.21, underscoring a prudent approach to leveraging.
Profitability and Growth Metrics
Regeneron Pharmaceuticals Inc excels in profitability, with a top-tier Profitability Rank and a Predictability Rank of 4.5 stars. The company's commitment to growth is demonstrated by a 16% 3-Year Revenue Growth Rate, outperforming 67.99% of its industry peers. Furthermore, its EBITDA has seen significant increases, with a three-year growth rate of 5 and a five-year rate of 17.7.
Conclusion: A Strong Candidate for Market Outperformance
Considering Regeneron Pharmaceuticals Inc's robust financial strength, impressive profitability, and consistent growth metrics, the GF Score highlights the company's exceptional position for potential market outperformance. Investors seeking similar opportunities can explore more companies with strong GF Scores through the GF Score Screen.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
